Skip to main content
Top
Published in: Applied Health Economics and Health Policy 1/2019

01-02-2019 | Original Research Article

Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States

Authors: Fang Xu, Yong Liu, Anne G. Wheaton, Kristina M. Rabarison, Janet B. Croft

Published in: Applied Health Economics and Health Policy | Issue 1/2019

Login to get access

Abstract

Background

Few studies have addressed recent trends in hospitalization costs for inflammatory bowel disease (IBD).

Objective

We explored trends and described patient and hospital factors associated with hospitalization costs for IBD.

Methods

Using data from the 2003–2014 National Inpatient Sample for adults aged ≥ 18 years, we estimated costs using multivariable linear models and assessed linear trends by time periods using piecewise linear regressions.

Results

In 2014, there were an estimated 56,290 hospitalizations for Crohn’s disease (CD), with a mean cost of US$11,345 and median cost of US$7592; and 33,585 hospitalizations for ulcerative colitis (UC), with a mean cost of US$13,412 and median cost of US$8873. Higher costs were observed among Hispanic [adjusted cost ratio (ACR) = 1.07; 95% confidence interval (CI) = 1.00–1.14; p = 0.04] or other non-Hispanic (ACR = 1.09; 95% CI = 1.02–1.17; p = 0.01) CD patients than for non-Hispanic White CD patients. For UC patients, higher costs were observed among men (ACR = 1.09; 95% CI = 1.05–1.13; p < 0.001) compared with women and among patients aged 35–44 years, 45–54 years, and 55–64 years compared with those aged 18–24 years. Among all patients, factors associated with higher costs included higher household income, more comorbidities, and hospitals that were government nonfederal versus private, were large versus small, and were located in the West versus Northeast regions. From 2003 to 2008, total costs increased annually by 3% for CD (1.03; 95% CI = 1.02–1.05; p < 0.001) and 4% for UC (1.04; 95% CI = 1.02–1.06; p < 0.001), but remained unchanged from 2008 to 2014.

Conclusions

The findings are important to identify IBD patients with higher hospitalization costs and to inform policy plans on hospital resource allocation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 Years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166–9.CrossRefPubMed Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 Years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166–9.CrossRefPubMed
2.
go back to reference Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10–20.CrossRefPubMed Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10–20.CrossRefPubMed
3.
go back to reference Vidal A, Gomez-Gil E, Sans M, et al. Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis. 2008;14:977–83.CrossRefPubMed Vidal A, Gomez-Gil E, Sans M, et al. Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis. 2008;14:977–83.CrossRefPubMed
4.
go back to reference Bokemeyer B, Hardt J, Huppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis. 2013;7:355–68.CrossRefPubMed Bokemeyer B, Hardt J, Huppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis. 2013;7:355–68.CrossRefPubMed
5.
go back to reference Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO. J Crohns Colitis. 2016;10:216–25.CrossRefPubMed Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO. J Crohns Colitis. 2016;10:216–25.CrossRefPubMed
6.
go back to reference Malarcher CA, Wheaton AG, Liu Y, et al. Hospitalizations for Crohn’s disease—United States, 2003–2013. MMWR Morb Mortal Wkly Rep. 2017;66:377–81.CrossRefPubMedPubMedCentral Malarcher CA, Wheaton AG, Liu Y, et al. Hospitalizations for Crohn’s disease—United States, 2003–2013. MMWR Morb Mortal Wkly Rep. 2017;66:377–81.CrossRefPubMedPubMedCentral
8.
go back to reference Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep. 2015;3:63–8.CrossRef Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep. 2015;3:63–8.CrossRef
9.
go back to reference Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996–1006.CrossRefPubMed Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996–1006.CrossRefPubMed
10.
go back to reference Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011;60:1178–81.CrossRefPubMed Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011;60:1178–81.CrossRefPubMed
11.
go back to reference Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–76.CrossRefPubMed Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–76.CrossRefPubMed
12.
go back to reference Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705–14.CrossRefPubMed Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705–14.CrossRefPubMed
13.
go back to reference Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–13.CrossRefPubMedPubMedCentral Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–13.CrossRefPubMedPubMedCentral
14.
go back to reference Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011;12:273–83.CrossRefPubMed Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011;12:273–83.CrossRefPubMed
15.
go back to reference Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261–72.CrossRefPubMed Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261–72.CrossRefPubMed
16.
go back to reference Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(385–392):e382. Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(385–392):e382.
28.
go back to reference Nguyen GC, Murthy SK, Bressler B, et al. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: a multicenter retrospective study. Inflamm Bowel Dis. 2017;23:695–701.CrossRefPubMed Nguyen GC, Murthy SK, Bressler B, et al. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: a multicenter retrospective study. Inflamm Bowel Dis. 2017;23:695–701.CrossRefPubMed
29.
go back to reference Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677–83.CrossRefPubMed Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677–83.CrossRefPubMed
30.
go back to reference Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309–17.CrossRefPubMed Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309–17.CrossRefPubMed
31.
go back to reference Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190–5.CrossRefPubMedPubMedCentral Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190–5.CrossRefPubMedPubMedCentral
32.
go back to reference Bahler C, Schoepfer AM, Vavricka SR, Brungger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29:916–25.CrossRefPubMed Bahler C, Schoepfer AM, Vavricka SR, Brungger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29:916–25.CrossRefPubMed
35.
go back to reference Stadnicki A. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol. 2012;10:659–69.CrossRefPubMed Stadnicki A. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol. 2012;10:659–69.CrossRefPubMed
36.
go back to reference Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1034–45.CrossRefPubMed Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1034–45.CrossRefPubMed
37.
go back to reference Hait E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis. 2005;11:519–27.CrossRefPubMed Hait E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis. 2005;11:519–27.CrossRefPubMed
38.
go back to reference Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18:1498–508.CrossRefPubMed Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18:1498–508.CrossRefPubMed
39.
go back to reference Sewell JL, Velayos FS. Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. Inflamm Bowel Dis. 2013;19:627–43.CrossRefPubMedPubMedCentral Sewell JL, Velayos FS. Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. Inflamm Bowel Dis. 2013;19:627–43.CrossRefPubMedPubMedCentral
40.
go back to reference Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014;8:288–95.CrossRefPubMed Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014;8:288–95.CrossRefPubMed
41.
go back to reference Weiss AJ, Elixhauser A. Overview of hospital stays in the United States, 2012: Statistical Brief #180. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006. Weiss AJ, Elixhauser A. Overview of hospital stays in the United States, 2012: Statistical Brief #180. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006.
42.
go back to reference Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ. 2014;2:e587.CrossRefPubMedPubMedCentral Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ. 2014;2:e587.CrossRefPubMedPubMedCentral
43.
go back to reference Stranges E, Holmquist L, Andrews RM. Inpatient stays in rural hospitals, 2007: Statistical Brief #85. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006. Stranges E, Holmquist L, Andrews RM. Inpatient stays in rural hospitals, 2007: Statistical Brief #85. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006.
44.
go back to reference Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61:622–9.CrossRefPubMed Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61:622–9.CrossRefPubMed
45.
go back to reference Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conentional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.CrossRefPubMedPubMedCentral Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conentional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.CrossRefPubMedPubMedCentral
46.
go back to reference Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–45.CrossRefPubMed Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–45.CrossRefPubMed
Metadata
Title
Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States
Authors
Fang Xu
Yong Liu
Anne G. Wheaton
Kristina M. Rabarison
Janet B. Croft
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 1/2019
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-018-0432-4

Other articles of this Issue 1/2019

Applied Health Economics and Health Policy 1/2019 Go to the issue